ReviewJournal of gynecologic oncology2015
Role of aggressive surgical cytoreduction in advanced ovarian cancer.
Review in Journal of gynecologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.Journal of robotic surgery · 2021Pooled it
- Impact of Lymphadenectomy on Outcomes of Early-Stage Ovarian Cancer: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology · 2018Trial
- Diagnostic performance of artificial intelligence for detecting peritoneal and small bowel dissemination in epithelial ovarian cancer using preoperative contrast-enhanced CT imaging.Scientific reports · 2026Article
- Role of immune cells in clear cell ovarian cancer: a two-sample bidirectional Mendelian randomization study.Journal of ovarian research · 2026Article
- Changes in Epithelial Ovarian Cancer Recurrence and Survival According to Treatment Paradigm Shifts.The journal of obstetrics and gynaecology research · 2026Article
- Comment on "survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer treated with platinum-based adjuvant chemotherapy".Turkish journal of medical sciences · 2026Article
- Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer.Frontiers in oncology · 2026Article
- Outcomes and prognostic factors in patients with synchronous endometrial and ovarian cancer.Archives of gynecology and obstetrics · 2025Article
- RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer.Scientific reports · 2025Article
- Impact of Bowel Resection on Operative Mortality and Overall Survival in Advanced Epithelial Ovarian Cancer.Cancers · 2025Article
- Current peritonectomy practice during debulking surgery in patients with newly diagnosed advanced ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 4004).Journal of gynecologic oncology · 2025Article
- Fluorescence-Guided Surgery to Detect Microscopic Disease in Ovarian Cancer: A Systematic Review with Meta-Analysis.Cancers · 2025Review
- Do all patients that undergo a 'complete' secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?Pleura and peritoneum · 2024Review
- Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study.Annals of surgical oncology · 2024Article
- Article
- Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.BMC urology · 2024Article
- Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.Gynecologic oncology · 2024Article
- Complicated pancreatic fistula after gynecologic surgery for left fallopian tube carcinosarcoma: A case report.Case reports in women's health · 2024Article
- Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ovarian cancer is the eighth most frequent cancer in women and is the most lethal gynecologic malignancy worldwide. The majority of ovarian cancer patients are newly diagnosed presenting with advanced-stage disease. Primary cytoreductive surgery and adjuvant taxane- and platinum-based combination chemotherapy are the standard treatment for advanced ovarian cancer. A number of studies have consistently shown that successful cytoreductive surgery and the resultant minimal residual disease are significantly associated with survival in patients with this disease. Much has been written and even more debated regarding the competing perspectives of biology of ovarian cancer versus the value of aggressive surgical resection. This review will focus on the current evidences and outcomes supporting the positive impact of aggressive surgical effort on survival in the primary management of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.